Biopharmaceutical CMO & CRO Market Worth $37.8 Billion by 2025: Grand View Research, Inc.

Tuesday, July 25, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, July 25, 2017 /PRNewswire/ --

The global biopharmaceutical CMO & CRO (contract manufacturing & research) market

 is expected to reach USD 37.8 billion by 2025, according to a new report by Grand View Research, Inc. Healthy outlook of biopharmaceuticals and consequent growth in biopharmaceutical pipelines has resulted into
lack of adequate capacity and budget constraints. These factors have convinced many traditional drug developers to take advantage of cost-saving benefits associated with contract services. Traditional biopharmaceutical players are observed to choose outsourcing biopharmaceutical manufacturing rather than making an investment of expensive capital in production equipment and hiring skilled labor.

     (Logo: )

Significant improvement in the services offered by this CMOs/CROs in context to maturity of complex technology is spurring the adoption of these services. In addition, wide acceptance of single-use technology within CMOs/CROs has significantly transformed the CMOs/CROs landscape by enhancing their capabilities and enabling them to develop products at low operating costs.

Outsourcing services are observed to play critical role in overcoming trade barriers for firms. It enables them to make footprints in foreign market where government regulates to secure local employment through domestic production. Furthermore, as a result of growing demand for these services, smaller companies have also begun to expand their non-GMP facilities.

Browse full research report with TOC on "Biopharmaceutical CMO & CRO Market Analysis By Source (Mammalian, Non-mammalian), By Service Type (Contract Manufacturing, Contract Research), By Product, And Segment Forecasts, 2014 - 2025" at:

Further key findings from the report suggest: 

  • Mammalian cell line-based bioproduction system dominated the share in 2016 in terms of revenue generation
  • This can be attributed to the presence of substantial number of mammalian-based manufacturing platforms offered by market leaders such as Lonza, Samsung BioLogics, WuXi Biologics
  • CMOs are providing wide range of services for entire chain of biopharmaceutical manufacturing process, consequently held the largest share
  • Growing R&D investment in bioproduction is the high impact rendering factor for the growth of CROs
  • Robust biologics pipeline and high production cost of biologics have contributed to the largest share of biologics outsourcing
  • Monoclonal antibodies accounted for significant share in 2016 owing to the huge success rate of MAbs for disease treatment
  • North America is home to large number of biopharmaceutical manufacturing entities, which in turn, have resulted into large share of this region
  • Being a lower wage country, China and India are expected to be fastest growing regional market
  • Several global companies are translocating their business to Asia Pacific owing to low manufacturing costs in Asian countries
  • Boehringer Ingelheim GmbH, Lonza, Samsung BioLogics, Patheon, FUJIFILM Diosynth Biotechnologies U.S.A., Inc. are some of the major companies operating in this space

Browse related reports by Grand View Research: 

  • Clinical Diagnostics Market-
  • Epigenetics Drugs and Diagnostic Technologies Market -
  • Mononucleosis Diagnostic Market -
  • Expression Vectors Market -

Grand View Research has segmented the global biopharmaceutical CMO & CRO market on the basis of source, service, product, and region: 

  • Source Outlook (Revenue, USD Million, 2014 - 2025) 
    • Mammalian
    • Non-mammalian
  • Service Outlook (Revenue, USD Million, 2014 - 2025) 
    • Contract Manufacturing
      • Process Development
        • Downstream
        • Upstream
      • Fill & Finish Operations
      • Analytical & QC studies
      • Packaging
    • Contract Research
      • Oncology
      • Inflammation & Immunology
      • Cardiology
      • Neuroscience
      • Others
  • Product Outlook (Revenue, USD Million, 2014 - 2025) 
    • Biologics
      • Monoclonal antibodies (MAbs)
      • Recombinant Proteins
      • Vaccines
      • Antisense, RNAi, & Molecular Therapy
      • Others
    • Biosimilars
  • Regional Outlook (Revenue, USD Million, 2014 - 2025) 
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
    • Asia Pacific
      • China
      • Japan
    • Latin America
      • Brazil
    • Middle East & Africa
      • South Africa

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Read Our Blogs -

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: +1-415-349-0058 Toll Free: +1-888-202-9519 Email:


SOURCE Grand View Research, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store